Iwatani Y, Kosugi K, Isobe-Oku S, Atagi S, Kitamura Y, Kawasaki H
Department of Clinical Pharmaceutical Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Br J Pharmacol. 2008 May;154(1):32-40. doi: 10.1038/bjp.2008.72. Epub 2008 Mar 10.
The vascular endothelium regulates vascular tone by releasing various endothelium-derived vasoactive substances to counteract excess vascular response. We investigated whether the vascular endothelium regulates vasodilatation via released endothelium-derived contracting factors (EDCFs), by examining the effect of endothelium removal on responses to periarterial nerve stimulation (PNS) and various vasodilator agents.
The rat mesenteric vascular bed was perfused with Krebs solution. Vasodilator responses to PNS and 5 min perfusion of vasodilator agents in preparations with endothelium were compared with those in the same preparations without endothelium. The endothelium was removed by 30 s perfusion with sodium deoxycholate.
Endothelium removal significantly augmented vasodilator responses to PNS and calcitonin gene-related peptide (CGRP), isoprenaline (beta-adrenoceptor agonist), SNP and 8-bromo-cGMP (8-Br-cGMP; cGMP analogue) but not BAY41-2272 (soluble guanylate cyclase activator). The augmentation of SNP-induced vasodilatation after denudation was much greater than that of CGRP- or isoprenaline-induced vasodilatation. In the preparations with an intact endothelium, L-NAME (nitric oxide synthase inhibitor) significantly augmented vasodilator responses to PNS and CGRP, isoprenaline, SNP and 8-Br-cGMP, but not BAY41-2272. Indomethacin (cyclooxygenase inhibitor) and seratrodast (thromboxane A(2) receptor antagonist), but not phosphoramidon (endothelin-1-converting enzyme inhibitor) or BQ-123 (selective endothelin type A receptor antagonists), significantly augmented vasodilator responses to PNS and CGRP, isoprenaline, SNP and BAY41-2272.
These results suggest that the endothelium in rat mesenteric arteries regulates and maintains vascular tone via counteracting not only vasoconstriction through releasing endothelium-derived relaxing factors, but also vasodilatation, in part by releasing an EDCF, thromboxane A(2).
血管内皮通过释放多种内皮源性血管活性物质来调节血管张力,以对抗过度的血管反应。我们通过研究去除内皮对动脉周围神经刺激(PNS)和各种血管扩张剂反应的影响,来探讨血管内皮是否通过释放内皮源性收缩因子(EDCFs)来调节血管舒张。
用 Krebs 溶液灌注大鼠肠系膜血管床。将有内皮的制剂中对 PNS 和血管扩张剂 5 分钟灌注的血管舒张反应与同一制剂去除内皮后的反应进行比较。通过用脱氧胆酸钠灌注 30 秒来去除内皮。
去除内皮显著增强了对 PNS、降钙素基因相关肽(CGRP)、异丙肾上腺素(β-肾上腺素能受体激动剂)、硝普钠(SNP)和 8-溴环鸟苷(8-Br-cGMP;cGMP 类似物)的血管舒张反应,但对 BAY41-2272(可溶性鸟苷酸环化酶激活剂)无影响。去内皮后 SNP 诱导的血管舒张增强远大于 CGRP 或异丙肾上腺素诱导的血管舒张增强。在有完整内皮的制剂中,L-NAME(一氧化氮合酶抑制剂)显著增强了对 PNS、CGRP、异丙肾上腺素、SNP 和 8-Br-cGMP 的血管舒张反应,但对 BAY41-2272 无影响。吲哚美辛(环氧化酶抑制剂)和塞曲司特(血栓素 A₂受体拮抗剂),而非磷酰胺(内皮素-1 转化酶抑制剂)或 BQ-123(选择性内皮素 A 型受体拮抗剂),显著增强了对 PNS、CGRP、异丙肾上腺素、SNP 和 BAY41-2272 的血管舒张反应。
这些结果表明,大鼠肠系膜动脉中的内皮不仅通过释放内皮源性舒张因子来对抗血管收缩,还通过释放一种 EDCF,即血栓素 A₂,部分调节和维持血管张力。